No connection

Search Results

APLS vs HTFL

APLS
Apellis Pharmaceuticals, Inc.
BEARISH
Price
$18.94
Market Cap
$2.42B
Sector
Healthcare
AI Confidence
85%
HTFL
Heartflow, Inc.
BEARISH
Price
$26.95
Market Cap
$2.31B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
APLS
105.22
HTFL
--
Forward P/E
APLS
-77.94
HTFL
-89.77
P/B Ratio
APLS
6.48
HTFL
7.65
P/S Ratio
APLS
2.41
HTFL
13.13
EV/EBITDA
APLS
42.6
HTFL
-34.43

Profitability

Gross Margin
APLS
60.34%
HTFL
76.8%
Operating Margin
APLS
-25.58%
HTFL
-36.13%
Profit Margin
APLS
2.23%
HTFL
-66.35%
ROE
APLS
7.48%
HTFL
-111.37%
ROA
APLS
3.53%
HTFL
-16.75%

Growth

Revenue Growth
APLS
-5.9%
HTFL
40.5%
Earnings Growth
APLS
--
HTFL
--

Financial Health

Debt/Equity
APLS
1.28
HTFL
0.07
Current Ratio
APLS
3.14
HTFL
5.2
Quick Ratio
APLS
2.59
HTFL
4.87

Dividends

Dividend Yield
APLS
--
HTFL
--
Payout Ratio
APLS
0.0%
HTFL
0.0%

AI Verdict

APLS BEARISH

APLS exhibits weak financial health per the Piotroski F-Score of 4/9, indicating a fragile foundation despite some positive gross margins and cash reserves. The company is unprofitable with negative operating margins and declining revenue, while insider selling activity and a bearish technical trend signal pessimism. Although the Graham Number ($3.44) and intrinsic value ($1.26) suggest deep undervaluation, the current price of $18.94 reflects high growth expectations that are not supported by fundamentals. The absence of an Altman Z-Score raises concern about default risk, especially given a debt/equity ratio of 1.28 and negative earnings. Analysts recommend 'buy' with a target of $33.60, but this optimism appears disconnected from deteriorating operational and financial trends.

Strengths
High gross margin of 60.34% indicates strong pricing power or low production costs
Current ratio of 3.14 and quick ratio of 2.59 suggest strong short-term liquidity
Positive earnings surprises in 2 out of the last 4 quarters (average +29.25%) show potential for upside in earnings execution
Risks
Piotroski F-Score of 4/9 indicates weak financial health and deteriorating fundamentals
Negative operating margin (-25.58%) and declining revenue (YoY -5.90%) signal ongoing operational inefficiencies
Insiders sold $1.47M worth of shares in the last 6 months with no buys, signaling lack of confidence
HTFL BEARISH

HTFL exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational inefficiency. While the company maintains a strong liquidity position (Current Ratio 5.20) and impressive revenue growth of 40.5%, these are offset by deep negative profit margins (-66.35%) and a high Price/Sales multiple of 13.13. The combination of heavy insider selling ($62.54M) and consistent earnings misses suggests a significant disconnect between analyst optimism and internal sentiment.

Strengths
Strong YoY revenue growth of 40.50%
High gross margins (76.80%) indicating a scalable product
Very low debt-to-equity ratio (0.07)
Risks
Critical financial health (Piotroski F-Score 1/9)
Severe profitability issues with -66.35% profit margins
Aggressive valuation (P/S 13.13) relative to earnings performance

Compare Another Pair

APLS vs HTFL: Head-to-Head Comparison

This page compares Apellis Pharmaceuticals, Inc. (APLS) and Heartflow, Inc. (HTFL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile